How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Varicose Veins Treatment Market
- By Treatment Type: Endovenous Laser Ablation (EVLA), Radiofrequency Ablation (RFA), Sclerotherapy, Surgical Ligation and Stripping, Foam Sclerotherapy, Phlebectomy
- By Product Type: Laser Devices, Radiofrequency Devices, Sclerosing Agents, Compression Stockings, Surgical Instruments
- By Patient Type: Primary Varicose Veins, Recurrent Varicose Veins, Chronic Venous Insufficiency
- By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Endovenous Laser Ablation (EVLA) leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 282 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.166 →
- 11 Company Profiles 17 players: SWOT & benchmarking p.174 →
Full report · locked preview
Everything inside the Varicose Veins Treatment Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →AngioDynamics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Cook Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Venous Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Philips Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →BTG plc (a Boston Scientific company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Venclose Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Biolitec AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Vascular Insights Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →VenaCure (a division of AngioDynamics)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Vasamed Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Covidien (now part of Medtronic)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Aesculap
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Endovenous Laser Ablation (EVLA)35.8
- Radiofrequency Ablation (RFA)15.8
- Sclerotherapy15.5
- Surgical Ligation and Stripping12.7
- Foam Sclerotherapy13.5
- Phlebectomy6.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic plc16.4
- Becton21.2
- Dickinson and Company (BD)6.4
- AngioDynamics Inc.9.9
- Cook Medical10.4
- Venous Medical7.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.6
- Europe22.1
- Asia Pacific19.8
- Latin America13.0
- Middle East and Africa9.5
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic plc | 84 | 83 | 74 | 98 | 95 | 96 | 88 |
| Becton | 81 | 71 | 72 | 83 | 75 | 80 | 77 |
| Dickinson and Company (BD) | 68 | 74 | 73 | 84 | 83 | 74 | 76 |
| AngioDynamics Inc. | 60 | 68 | 78 | 64 | 64 | 72 | 68 |
| Cook Medical | 67 | 59 | 74 | 58 | 74 | 72 | 67 |
| Venous Medical | 69 | 67 | 53 | 52 | 54 | 52 | 58 |
| Siemens Healthineers | 41 | 56 | 43 | 52 | 41 | 55 | 48 |
| Philips Healthcare | 54 | 57 | 53 | 43 | 41 | 44 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic plc
- Becton
- Dickinson and Company (BD)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic plc | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Becton | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Dickinson and Company (BD) | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| AngioDynamics Inc. | − | ✓ | ✓ | − | ✓ | ◐ |
| Cook Medical | ◐ | − | ◐ | − | ✓ | ◐ |
| Venous Medical | − | ✓ | ◐ | ◐ | − | − |
| Siemens Healthineers | − | ◐ | − | − | − | − |
| Philips Healthcare | ◐ | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Challenger4
Strong scale, closing on the leaders.
Contender1
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Treatment Type in North America, then scale across Varicose Veins Treatment Market — a $287M beachhead inside a $5.24B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Endovenous Laser Ablation (EVLA)
Best fit — highest urgency & budget in Treatment Type.
Radiofrequency Ablation (RFA)
Strong fit — clear ROI and a fast path to value.
Sclerotherapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Product Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Varicose Veins Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Varicose Veins Treatment Market is a durable-growth opportunity — $2.96B by 2033, compounding at 8.0%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.0% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Product Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Varicose Veins Treatment Market — a $5.10B market by 2033. Plan: grow share from 7.5% to 16.2%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.5% | 16.2% | On track |
| Revenue | $373M | $826M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 34.0% | 42.3% | At risk |
| Customer retention | 86.3% | 93.9% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Product Type capability
A defensible second engine — invest in Product Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Product Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $122M capacity & capability investment
- Greenlight bolt-on M&A in Product Type
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAt risk
Sales deck · value proposition
Win the Varicose Veins Treatment Market conversation — a $7.01B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Varicose Veins Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Varicose Veins Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Variegated Vinyl Siding Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportVarifocal Camera Objective Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportVariode Market
Market size, share, segmentation and regional forecast.
$393M market · 2025 base year
View reportVaristor Arrester Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportVaristor Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportVaristor UL1449 3rd Edition Safety Agency Update Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportVarnishes Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportVarnishes, Coatings, and Paints Market
Market size, share, segmentation and regional forecast.
$349M market · 2025 base year
View reportVascular Access Consumables Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportVascular Access Devices and Accessories Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportVascular Access Hemostasis Valves Market
Market size, share, segmentation and regional forecast.
$621M market · 2025 base year
View reportVascular Access Systems Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy